Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
273 hedge funds and large institutions have $2.77B invested in Apellis Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 60 funds opening new positions, 93 increasing their positions, 91 reducing their positions, and 31 closing their positions.
384% more call options, than puts
Call options by funds: $102M | Put options by funds: $21.1M
94% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 31
22% more capital invested
Capital invested by funds: $2.28B → $2.77B (+$493M)
11% more funds holding
Funds holding: 247 → 273 (+26)
2% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 91
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
7.8% less ownership
Funds ownership: 104.66% → 96.86% (-7.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$39.3M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$30.3M |
| 3 |
Millennium Management
New York
|
+$26.6M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$23.3M |
| 5 |
IG
ING Group
Amsterdam,
Netherlands
|
+$20.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$197M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$53.8M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$34.7M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$30.4M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$24.3M |
APLS Hedge Fund Activity: Q3 2025 in Review
273 of the 7,631 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q3 2025, worth a combined $2.77B — up 22% from $2.28B a quarter earlier.
Buyers outnumbered sellers: 60 funds opened new APLS positions and 31 closed out — a net gain of 29 holders — while 93 added to existing stakes and 91 trimmed.
The largest buyer was Jennison Associates, adding an estimated $39.3M. The largest seller was EcoR1 Capital, cutting an estimated $197M.
- 273 institutional investors held Apellis Pharmaceuticals (APLS) as of Q3 2025, up from 247 in Q2 2025.
- Funds reported $2.77B of Apellis Pharmaceuticals stock for Q3 2025, up 22% quarter-over-quarter.
- 60 funds opened new Apellis Pharmaceuticals positions in Q3 2025 and 31 closed out, a net change of +29 holders.
- The largest Apellis Pharmaceuticals buyer in Q3 2025 was Jennison Associates, an estimated $39.3M added.
- The largest Apellis Pharmaceuticals seller in Q3 2025 was EcoR1 Capital, an estimated $197M sold.
Based on aggregated 13F filings for Q3 2025.